Stock Report

Download full stock data and analysis for free Last Updated: 27-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Jagsonpal Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: JAGSNPHARM | BSE: 507789

₹223.11

up-down-arrow ₹0.05 (0.02%)

As on 27-Oct-2026IST

Market cap

info icon

₹1,473 Cr

Revenue (TTM)

info icon

₹294 Cr

P/E Ratio

info icon

32.4

P/B Ratio

info icon

6.4

Div. Yield

info icon

2.5 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 28.08 8.76 3.87 7.54 6.91
EBIT 70.79 27.30 13.66 14.89 16.08
Net Profit 50.52 22.18 12.52 14.57 17.08
EPS 53.10 23.46 8.90 12.71 15.93
Book Value -- -- 16.31 18.54 16.99
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 14.3913.5817.6516.9315.98
Net Margin info 14.9012.8514.8714.4019.99
Return on equity info 20.2418.9817.7918.1928.51
Return on Capital info 24.5223.79--22.6933.14
Return on Assets info 15.5714.4515.2914.1822.02
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
22.69
33.14
17.72
24.15
Peer Median
--
21.39
21.76
21.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

17.79

Higher than Peers by 2.78

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
17.79
18.19
28.51
14.02
18.89
Peer Median
15.01
18.19
17.93
16.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

15.29

Higher than Peers by 5.21

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
15.29
14.18
22.02
10.52
14.29
Peer Median
10.08
9.89
12.81
12.32
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

17.65

Higher than Peers by 0.67

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
17.65
16.93
15.98
10.26
13.92
Peer Median
16.98
17.80
18.93
21.05
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

14.87

Higher than Peers by 1.55

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
14.87
14.40
19.99
10.31
11.02
Peer Median
13.32
13.31
14.94
15.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
17.25
22.53
10.75
10.86
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

3.87

Lower than Peers by 8.52

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
3.87
6.89
28.76
-11.83
8.79
Peer Median
12.40
12.57
10.90
13.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

13.66

Lower than Peers by 9.33

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
13.66
13.25
100.62
-35.04
40.20
Peer Median
22.99
14.32
15.01
23.50
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

12.52

Lower than Peers by 9.95

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
12.52
-22.18
146.45
-15.94
41.72
Peer Median
22.47
12.41
14.80
30.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

8.90

Lower than Peers by 10.66

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
8.90
-22.84
145.32
-16.70
41.72
Peer Median
19.56
14.40
14.27
29.02
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
17.30
27.98
13.46
13.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
--
--
--
--
Peer Median
0.00
0.05
0.06
0.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

5.06

Higher than Peers by 2.95

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
5.06
3.81
6.22
9.39
4.89
Peer Median
2.11
1.95
1.90
2.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

4.54

Higher than Peers by 2.96

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
4.54
3.45
5.64
8.61
4.31
Peer Median
1.58
1.58
1.46
1.59
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

60.28

Higher than Peers by 37.37

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
60.28
56.95
73.92
37.69
85.28
Peer Median
22.92
20.88
24.96
45.29
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

5.85

Lower than Peers by 14.71

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
5.85
5.99
4.90
5.25
8.82
Peer Median
20.56
19.75
21.77
20.10
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.99

Higher than Peers by 0.25

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
0.99
1.00
1.12
1.05
1.38
Peer Median
0.73
0.78
0.76
0.81
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
18.20
15.63
25.88
25.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
17.89
19.56
29.02
35.78
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
37.27
32.80
55.17
69.43
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
--
-1.18
2.39
-0.27
-7.78
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

32.39

Lower than Peers by 0.05

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
32.39
28.65
25.90
13.17
11.37
Peer Median
32.44
32.45
26.81
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

6.40

Higher than Peers by 2.11

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
6.40
4.83
6.58
4.34
5.06
Peer Median
4.28
4.70
4.65
6.11
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

2.47

Higher than Peers by 1.98

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
2.47
2.98
1.16
1.79
1.72
Peer Median
0.48
0.50
0.61
0.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

18.69

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
18.69
16.10
22.02
18.30
16.17
Peer Median
--
24.86
27.02
34.57
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,473

Lower than Peers by 13,856

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Jagsonpal Pharma
1,473
1,234
1,434
740
759
Peer Median
15,329
15,187
20,914
25,297
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds